With Partner Lilly, TVM Capital Gets A Canadian Makeover
This article was originally published in Start Up
One of two venture firms signed up to run an Eli Lilly “mirror portfolio” of single-asset companies, venerable TVM Capital has made significant changes to get its new model off the ground.
You may also be interested in...
Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly
Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.
CMEA Ventures Into Development, But Not Tied To Lilly As Expected
Several biopharma venture investors are experimenting with new models to avoid the long timelines and massive pay checks typically required to nurture new biotech companies. One of those investors, CMEA Capital of San Francisco, officially debuted its model Thursday, June 23, but not before making a major strategic shift.
Lilly's Evolving Corporate Venture Model
Of all the big pharmaceutical companies, Eli Lilly & Co. has arguably been the most aggressive and creative in finding outsiders to help develop their drugs. With its latest venture, Lilly hopes to learn lessons from a past failed initiative. The Indianapolis drug firm is set to put up to $150 million to work, backing three traditional venture funds as part of a strategy that outsources development of its own molecules.